

RECEIVED
CENTRAL FAX CENTER

MAY 12 2005

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/808,889	
	Filing Date	March 25, 2004	
	First Named Inventor	François CLERC et al.	
	Art Unit	1626	
	Examiner Name	LEE, Susannah E.	
Total Number of Pages in This Submission	25 pgs.	Attorney Docket Number	ST01027 US CNT

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): <div style="border: 1px solid black; height: 40px; width: 100%;"></div>
Remarks 1. AMENDMENT WITH REPLY - 24 PGS.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	AVENTIS PHARMACEUTICALS INC.	
Signature	<i>Balaram Gupta</i>	
Printed name	Balaram Gupta	
Date	May 12, 2005	Reg. No. 40,009

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306; Total No. of Pages Transmitted: 25 pgs.)		
Signature	<i>Maribel Mendez</i>	
Typed or printed name	Maribel Mendez	Date May 12, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT**Docket No.: ST01027 US CNT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****In re Application of
Francois Clerc****Examiner: Lee, Susannah E.****Serial No.: 10/808,889****Art Unit: 1626****Filed: March 25, 2004****TELEFAX CERTIFICATE****Title: Substituted Benzimidazole Compounds
and Their Use For the Treatment of
Cancer**

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, at (703) 872-9306 on

5/12/05
Date of Transmission

[Signature]
Signature

**Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450**

**AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 AND REPLY
PURSUANT TO 37 C.F.R. § 1.111**

Sir:

This is a Rule 111 Amendment in the above-identified patent application in response to the Office Action, paper no. 021005, dated February 18, 2005, having a response due by May 18, 2005. It is respectfully requested that the following amendments and remarks be entered in this case.

Amendments to specification start on page 2.

Amendments to claims start on page 5.

Remarks to amendments and the outstanding office action begin on page 18.

ST01027 US CNT

-1 of 23-